1919820-28-2
1919820-28-2
Chemical Structure
Pariceract
Synonym(s): LTI-291; BIA 28-6156
- CAS No.: 1919820-28-2
- Formula:C20H30N4O2
- Molecular Weight:358.48
IUPAC Name: 5,7-dimethyl-N-((1r,4r)-4-(pentyloxy)cyclohexyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide
InChIKey: HZILSILAELSWKN-QAQDUYKDSA-N
SMILES: O=C(C1=C2N=C(C)C=C(C)N2N=C1)N[C@@H]3CC[C@@H](OCCCCC)CC3
Biological Activity: Pariceract (LTI-291) is an activator of glucocerebrosidase (Gcase), with activation rates of more than 60% (1 μM) and between 10%-20% (0.1 μM). Pariceract can be used for Parkinson's disease and endometriosis research[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Pariceract | 99.11% | Pariceract (LTI-291) is an activator of glucocerebrosidase (Gcase), with activation rates of more than 60% (1 μM) and between 10%-20% (0.1 μM). Pariceract can be used for Parkinson's disease and endometriosis research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Pariceract (Standard) | ≥98% | Pariceract (Standard) is the analytical standard of Pariceract (HY-104038). This product is intended for research and analytical applications. Pariceract (LTI-291) is an activator of glucocerebrosidase (Gcase), with activation rates of more than 60% (1 μM) and between 10%-20% (0.1 μM). Pariceract can be used for Parkinson's disease and endometriosis research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
